We are live on
!
Find out more
Perceptive Advisors Portfolio holdings
AUM
$6.66B
Turnover
32.23%
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.54%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$5.12B
AUM Growth
-$493M
(-8.8%)
Cap. Flow
-$685M
Cap. Flow
% of AUM
-13.38%
Top 10 Holdings %
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42
Avg Time Held Equity + Options
1.5
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
0.7
years
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
0.7
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$101M |
| 2 |
Relay Therapeutics
RLAY
|
+$70.2M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$59.9M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$39.8M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$33.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exact Sciences
EXAS
|
+$122M |
| 2 |
Arcellx
ACLX
|
+$95.6M |
| 3 |
Boston Scientific
BSX
|
+$93.3M |
| 4 |
Amicus Therapeutics
FOLD
|
+$90.7M |
| 5 |
Astria Therapeutics
ATXS
|
+$84.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.61% |
| 2 | Miscellaneous | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
CALL
Ocular Therapeutix
OCUL
$1.62B
| $4.24M | 0.08% |
+500,000
| New | +$4.77M |
2026 Q1
0 quarters
|
|
77
ADMA Biologics
ADMA
$2.4B
| $4.21M | 0.08% |
467,233
-416,235
| -47% | -$6.57M |
2016 Q3
38 quarters
|
|
78
Inhibikase Therapeutics
IKT
$255M
| $3.89M | 0.08% |
2,315,000
-3,106,568
| -57% | -$5.52M |
2024 Q4
5 quarters
|
|
79
Crescent Biopharma
CBIO
$464M
| $3.8M | 0.07% |
206,942
-246,744
| -54% | -$2.83M |
2025 Q2
3 quarters
|
|
80
DELISTED
Apellis Pharmaceuticals
APLS
| $3.26M | 0.06% |
+80,956
| New | +$1.74M |
2026 Q1
0 quarters
|
|
81
Outset Medical
OM
$76.7M
| $3.2M | 0.06% |
833,333
| – | – |
2025 Q1
4 quarters
|
|
82
Edesa Biotech
EDSA
$25.7M
| $2.95M | 0.06% |
+563,239
| New | +$1.69M |
2026 Q1
0 quarters
|
|
83
Adaptive Biotechnologies
ADPT
$4.08B
| $2.12M | 0.04% |
+152,500
| New | +$2.43M |
2026 Q1
0 quarters
|
|
84
Avalo Therapeutics
AVTX
$644M
| $2.09M | 0.04% |
139,667
| – | – |
2025 Q1
4 quarters
|
|
85
Connect Biopharma Holdings
CNTB
$57.1M
| $2.08M | 0.04% |
792,696
| – | – |
2025 Q4
1 quarter
|
|
86
Corcept Therapeutics
CORT
$12.3B
| $2.02M | 0.04% |
+50,000
| New | +$1.87M |
2026 Q1
0 quarters
|
|
87
Medline Inc
MDLN
$32.1B
| $1.25M | 0.02% |
28,000
| – | – |
2025 Q4
1 quarter
|
|
88
Palatin Technologies
PTN
$11.6M
| $1.08M | 0.02% |
61,945
-8,055
| -12% | -$153K |
2025 Q4
1 quarter
|
|
89
Cumberland Pharmaceuticals
CPIX
$113M
| $640K | 0.01% |
196,978
-144,109
| -42% | -$555K |
2025 Q4
1 quarter
|
|
90
Revolution Medicines Inc Warrant
RVMDW
$108M
| $448K | 0.01% |
250,000
| – | – |
2023 Q4
9 quarters
|
|
91
Exagen
XGN
$207M
| $345K | 0.01% |
+114,893
| New | +$444K |
2026 Q1
0 quarters
|
|
92
Ensysce Biosciences
ENSC
$11.6M
| $46.7K | ﹤0.01% |
86,666
| – | – |
2024 Q4
5 quarters
|
|
93
DELISTED
Surrozen Inc Warrant
SRZNW
| $2.67K | ﹤0.01% |
166,666
| – | – |
2021 Q3
18 quarters
|
|
|
94
DELISTED
Arcellx
ACLX
| – | – |
-1,466,071
| Closed | -$95.6M | – |
|
95
Aldeyra Therapeutics
ALDX
$44.5M
| – | – |
-4,185,632
| Closed | -$21.7M | – |
|
96
Aquestive Therapeutics
AQST
$510M
| – | – |
-747,193
| Closed | -$4.83M | – |
|
|
97
DELISTED
Astria Therapeutics
ATXS
| – | – |
-6,485,420
| Closed | -$84.9M | – |
|
98
Biodesix
BDSX
$261M
| – | – |
-108,694
| Closed | -$739K | – |
|
99
CALL
Biohaven
BHVN
$1.73B
| – | – |
-500,000
| Closed | -$5.64M | – |
|
100
Biogen
BIIB
$34.8B
| – | – |
-124,000
| Closed | -$21.8M | – |
|
Similar funds
Perceptive Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Perceptive Advisors withdrew a net $685M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Miscellaneous.
Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.
- Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
- Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
- Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
- Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
- Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
- Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
- Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.